Abstract:Peptides are receiving increasing interest as clinical therapeutics. These highly tunable molecules can be tailored to achieve desirable biocompatibility and biodegradability with simultaneously selective and potent therapeutic effects. Despite challenges regarding up-scaling and licensing of peptide products, their vast clinical potential is reflected in the 60 plus peptide-based therapeutics already on the market, and the further 500 derivatives currently in developmental stages. Peptides are proving effective for a multitude of disease states including: type 2 diabetes (controlled using the licensed glucagon-like peptide-1 receptor liraglutide); irritable bowel syndrome managed with linaclotide (currently at approval stages); acromegaly (treated with octapeptide somatostatin analogues lanreotide and octreotide); selective or broad spectrum microbicidal agents such as the Gram-positive selective PTP-7 and antifungal heliomicin; anticancer agents including goserelin used as either adjuvant or monotherapy for prostate and breast cancer, and the first marketed peptide derived vaccine against prostate cancer, sipuleucel-T. Research is also focusing on improving the biostability of peptides. This is achieved through a number of mechanisms ranging from replacement of naturally occurring L-amino acid enantiomers with D-amino acid forms, lipidation, peptidomimetics, N-methylation, cyclization and exploitation of carrier systems. The development of self-assembling peptides are paving the way for sustained release peptide formulations and already two such licensed examples exist, lanreotide and octreotide. The versatility and tunability of peptide-based products is resulting in increased translation of peptide therapies, however significant challenges remain with regard to their wider implementation. This review highlights some of the notable peptide therapeutics discovered to date and the difficulties encountered by the pharmaceutical industry in translating these molecules to the clinical setting for patient benefit, providing some possible solutions to the most challenging barriers.

USFDA-approved parenteral peptide formulations and excipients: Industrial perspective

Polymeric-based particulate systems for delivery of therapeutic proteins.

An expanding horizon of complex injectable products: development and regulatory considerations

Development and approval of novel injectables: enhancing therapeutic innovations

Systemic delivery of peptides by the oral route: Formulation and medicinal chemistry approaches

The industrial design, translation, and development strategies for long-acting peptide delivery

PEGylation and Cell-Penetrating Peptides: Glimpse into the Past and Prospects in the Future

Natural and Synthetic Polymers As Drug Carriers for Delivery of Therapeutic Proteins

Stabilization and delivery approaches for protein and peptide pharmaceuticals: an extensive review of patents

Analytical and drug delivery strategies for short peptides: From manufacturing to market

Exploring FDA-Approved Frontiers: Insights into Natural and Engineered Peptide Analogues in the GLP-1, GIP, GHRH, CCK, ACTH, and α-MSH Realms

Advancements in peptide-based therapeutics: Design, synthesis and clinical applications

Excipients and their use in injectable products

Challenges of peptide and protein drug delivery by oral route: Current strategies to improve the bioavailability

Current Status and Perspectives of Oral Therapeutic Protein and Peptide Formulations: A Review

Therapeutic Peptides and Proteins: Stabilization Challenges and Biomedical Applications by Means of Nanodelivery Systems

Peptide Therapeutics and the Pharmaceutical Industry: Barriers Encountered Translating from the Laboratory to Patients

Current Advancements on Oral Protein and Peptide Drug Delivery Approaches to Bioavailability: Extensive Review on Patents

Review on therapeutic potential of peptides: Advancements in synthesis methods, linear and cyclic peptides, and strategies for overcoming challenges

Engineering peptide drug therapeutics through chemical conjugation and implication in clinics

Oral peptide and protein delivery: intestinal obstacles and commercial prospects